Chronic Myeloid Leukemia - Pipeline Insight, 2024

This “Chronic Myeloid Leukaemia- Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Myeloid Leukaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Myeloid Leukaemia Understanding

Chronic Myeloid Leukaemia: Overview

Chronic myeloid leukaemia (CML) is a type of cancer that affects the white blood cells and tends to progress slowly over many years. It can occur at any age, but is most common in older adults around 60-65 years of age. In CML, the spongy material inside some bones (bone marrow) produces too many myeloid cells - immature white blood cells that are not fully developed and do not work properly. CML does not usually cause any symptoms in its early stages and may only be picked up during tests carried out for another reason. As the condition develops, symptoms can include: tiredness, weight loss, night sweats, tenderness and swelling in the left side of your tummy, feeling full after small meals, pale skin and shortness of breath. Treatment for CML is usually started straight away to help slow down its progression and keep it under control. The main treatments for CML are medicines called tyrosine kinase inhibitors that stop the cancer cells growing and multiplying. They can help keep CML under control if taken for life. CML is a serious and life-threatening condition, but with the introduction of newer tyrosine kinase inhibitors, the outlook is much better now than it used to be. It is estimated that around 70% of men and 75% of women will live for at least 5 years after their diagnosis. Younger adults tend to have a better outlook than older adults. CML is caused by a genetic change (mutation) in the stem cells produced by the bone marrow. The mutation causes the stem cells to produce too many underdeveloped white blood cells. It also leads to a reduction in the number of other blood cells, such as red blood cells.

Chronic Myeloid Leukaemia- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Myeloid Leukaemia pipeline landscape is provided which includes the disease overview and Chronic Myeloid Leukaemia treatment guidelines. The assessment part of the report embraces, in depth Chronic Myeloid Leukaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Myeloid Leukaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myeloid Leukaemia R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Myeloid Leukaemia.

Chronic Myeloid Leukaemia Emerging Drugs Chapters

This segment of the Chronic Myeloid Leukaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Myeloid Leukaemia Emerging Drugs

Navtemadlin : Kartos Therapeutics Navtemadlin (KRT-232) is a novel, potent, and selective oral MDM2 inhibitor. Currently, the drug is undergoing an Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML).

Ropeginterferon alfa 2b : AOP Orphan Pharmaceuticals Ropeginterferon alfa-2b was discovered by Pharma Essentia Corp. based in Taiwan. BESREMi (Ropeginterferon alfa-2b) is a novel, long-acting, mono-pegylated proline interferon .Its pharmacokinetic properties offer a new level oftolerability.

Chronic Myeloid Leukaemia: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Myeloid Leukaemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Myeloid Leukaemia

There are approx. 20+ key companies which are developing the therapies for Chronic Myeloid Leukaemia. The companies which have their Chronic Myeloid Leukaemia drug candidates in the most advanced stage, i.e. phase II include, AOP Orphan Pharmaceuticals.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Myeloid Leukaemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Myeloid Leukaemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Myeloid Leukaemia drugs.

Chronic Myeloid Leukaemia Report Insights

• Chronic Myeloid Leukaemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Myeloid Leukaemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Myeloid Leukaemia drugs?
• How many Chronic Myeloid Leukaemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Myeloid Leukaemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Myeloid Leukaemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Myeloid Leukaemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Kartos Therapeutics
• AOP Orphan Pharmaceuticals
• Biokine Therapeutics
• Incyte Corporation
• Sana Biotechnology
• Novartis
• Nerviano Medical Sciences
• Sun Pharma Advanced Research Company

Key Products

• KRT-232
• BESREMi
• Motixafortide
• Ruxolitinib
• SC-291
• Asciminib
• Danusertib
• Vodobatinib

This product will be delivered within 1-3 business days.